Viewpoint Molecular Targeting (now Perspective Therapeutics) is a radiopharmaceutical company specializing in targeted alpha-particle therapy (TAT) using Lead-212 to treat cancer. They use a "theranostic" approach, combining imaging with Pb therapy to identify and treat metastatic melanoma (VMT01) and neuroendocrine tumors.